Retension Pharmaceuticals has announced a scientific advisory board to support development of RTN-001, its investigational drug for hypertension. In a company release distributed by Business Wire and published on BioSpace, Retension said the group would provide scientific, clinical-trial and therapeutic-area guidance while an ongoing Phase 2b study evaluates the candidate.
The announcement concerns the company’s advisory structure and development program. It does not report new results from the Phase 2b trial or announce regulatory approval. The distinction matters because the release also includes the company’s account of earlier research and its expectations for what RTN-001 might achieve.
Who Is Joining the Advisory Board
The release names five inaugural members with backgrounds in hypertension, cardiovascular medicine and nephrology. Omar Al Dhaybi is identified as director of the American Heart Association Comprehensive Hypertension Center at Mount Sinai Fuster Heart Hospital and an assistant professor at the Icahn School of Medicine at Mount Sinai.
James L. Januzzi is listed as the Adolph Hutter Professor of Medicine at Harvard Medical School, a member of the Massachusetts General Hospital Cardiology Division, and chief scientific officer and C. Michael Gibson Chair at the Baim Institute for Clinical Research. These are affiliations reported in the announcement, not institutional endorsements of the investigational drug.
Luke J. Laffin is identified with Cleveland Clinic’s Preventive Cardiology and Rehabilitation Section and as medical director of its Coordinating Center for Clinical Research. The release also lists an associate professorship at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. Laffin chairs the steering committee for Retension’s Phase 2b trial.
Ian Wilkinson is professor of therapeutics at the University of Cambridge, director of the Cambridge Clinical Trials Unit and Office of Translational Research, and president of the British and Irish Hypertension Society. Randall M. Zusman is director of the Division of Hypertension at Massachusetts General Hospital Heart Center and an associate professor at Harvard Medical School.
Retension said the board’s combined expertise includes hypertension diagnosis and management, cardiorenal disease treatment, and the design and conduct of cardiovascular clinical trials. That describes the areas in which the company expects advice; appointing specialists does not itself establish a trial outcome.
What the Release Says About RTN-001
Retension describes itself as a clinical-stage biopharmaceutical company developing medicines for hypertension and other cardiovascular diseases. Its lead candidate, RTN-001, is being developed for patients with uncontrolled and resistant hypertension. The announcement does not provide treatment recommendations or identify which individual patients should receive the investigational drug.
According to the company, RTN-001 is a cardiovascular-targeted, next-generation PDE5 inhibitor designed to enhance nitric oxide signaling in central arteries that first-generation PDE5 inhibitors do not adequately reach. This is the sponsor’s description of the candidate’s intended mechanism. It should not be broadened into a claim that all existing blood-pressure medicines share that limitation.
The company says RTN-001 has been studied in multiple clinical trials totaling 265 subjects. It also describes clinically meaningful blood-pressure reductions and an efficacy and safety profile in patients and healthy volunteers. The release does not give a trial-by-trial enrollment breakdown, doses, comparative results, blood-pressure measurements or adverse-event rates.
Those omissions limit what can be concluded from this announcement alone. The 265-subject figure covers multiple studies; it is not presented as the enrollment of the ongoing Phase 2b trial. The company’s qualitative claims should therefore remain attributed claims, not be restated as independently established evidence of benefit or safety.
Advice for an Ongoing Development Program
Chief executive Eric Keller said the advisors’ experience would help guide the program through Phase 2b. Chief medical officer Alison D. Schecter said their involvement would strengthen trial execution and thinking about RTN-001 beyond the current study. Both statements describe management’s expectations for the board’s contribution.
The release says the Phase 2b trial is ongoing and refers to advancing toward topline data, but supplies no readout date. It does not detail the trial’s endpoints, enrollment target or regulatory submission timetable. The advisory-board announcement should not be treated as a substitute for those study details or eventual reported results.
Retension says it is developing RTN-001 under an exclusive worldwide license from Sanofi. For now, the concrete development is the formation of the advisory board around an existing clinical program. Any assessment of the candidate’s future medical role will require evidence beyond the personnel appointments and company statements in this release.
